HK1042234A1 - 向肺部施加乾粉配方以治疗不育症 - Google Patents

向肺部施加乾粉配方以治疗不育症 Download PDF

Info

Publication number
HK1042234A1
HK1042234A1 HK02103235.7A HK02103235A HK1042234A1 HK 1042234 A1 HK1042234 A1 HK 1042234A1 HK 02103235 A HK02103235 A HK 02103235A HK 1042234 A1 HK1042234 A1 HK 1042234A1
Authority
HK
Hong Kong
Prior art keywords
dry powder
treating infertility
pulmonary administration
powder formulations
methods
Prior art date
Application number
HK02103235.7A
Other languages
English (en)
Chinese (zh)
Inventor
Nagarajan Sudha
S. Patton John
B. Bennett David
Greene Joanne
Chiang Hi-Shi
L. M. Stults Cheryl
Venthoye Geraldine
Lavern Allen Darrel
Lee Hughes Benjamin
Stiff-Torvik Mary
Keith Wolff Ronald
David Roeder William
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Priority claimed from PCT/US2000/009869 external-priority patent/WO2000061178A1/en
Publication of HK1042234A1 publication Critical patent/HK1042234A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
HK02103235.7A 1999-04-13 2000-04-13 向肺部施加乾粉配方以治疗不育症 HK1042234A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12912199P 1999-04-13 1999-04-13
US129121P 1999-04-13
US13009999P 1999-04-20 1999-04-20
US130099P 1999-04-20
PCT/US2000/009869 WO2000061178A1 (en) 1999-04-13 2000-04-13 Pulmonary administration of dry powder formulations for treating infertility

Publications (1)

Publication Number Publication Date
HK1042234A1 true HK1042234A1 (zh) 2002-08-09

Family

ID=26827234

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02103235.7A HK1042234A1 (zh) 1999-04-13 2000-04-13 向肺部施加乾粉配方以治疗不育症

Country Status (7)

Country Link
US (1) US7112341B1 (https=)
EP (1) EP1169053A1 (https=)
JP (1) JP2002541213A (https=)
AU (1) AU779869B2 (https=)
CA (1) CA2369262A1 (https=)
HK (1) HK1042234A1 (https=)
TW (1) TWI277425B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ518401A (en) * 1999-10-29 2004-01-30 Nektar Therapeutics Dry powder compositions having improved dispersivity
WO2004096113A2 (en) * 2003-04-28 2004-11-11 Medical Instill Technologies, Inc. Container with valve assembly for filling and dispensing substances, and apparatus and method for filling
JP4933439B2 (ja) * 2004-11-09 2012-05-16 アレス トレーディング ソシエテ アノニム Ｆｓｈの精製方法
EP1960419B1 (en) * 2005-12-09 2016-03-16 Ares Trading S.A. Method for purifying fsh or a fsh mutant
WO2007127286A2 (en) 2006-04-24 2007-11-08 Medical Instill Technologies, Inc. Needle penetrable and laser resealable lyophilization device and related method
JP2010533181A (ja) * 2007-07-13 2010-10-21 アボツト・バイオテクノロジー・リミテツド ＴＮＦα阻害剤の肺投与のための方法及び組成物
CA2742802C (en) 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
CA2766565A1 (en) 2009-06-23 2010-12-29 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
SG182408A1 (en) 2010-01-11 2012-08-30 Alexion Pharma Inc Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
MX340696B (es) 2010-04-30 2016-07-21 Alexion Pharma Inc Anticuerpos anti-c5a y metodos para usar los anticuerpos.
JP6019118B2 (ja) * 2011-08-02 2016-11-02 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニＳｉｇｍａ−Ｔａｕ Ｉｎｄｕｓｔｒｉｅ Ｆａｒｍａｃｅｕｔｉｃｈｅ Ｒｉｕｎｉｔｅ Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ 吸入に適した酸化型アビジンの医薬品組成物
RU2668174C2 (ru) * 2012-07-30 2018-09-26 Трофоген Инк. Суперагонисты гликопротеинового гормона длительного действия
US10457713B2 (en) 2012-07-30 2019-10-29 Trophogen, Inc. Glycoprotein hormone long-acting superagonists
CN105873602A (zh) 2013-11-05 2016-08-17 特洛佛根股份有限公司 糖蛋白激素长效超激动剂
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
CA3024618A1 (en) 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
DK3658184T5 (da) 2017-07-27 2024-08-26 Alexion Pharma Inc Højkoncentrerede anti-c5-antistofformuleringer
CN118512588A (zh) 2017-10-26 2024-08-20 亚力兄制药公司 用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用
WO2019126536A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals Inc. Humanized anti-cd200 antibodies and uses thereof
EP3802593B1 (en) 2018-05-31 2024-09-11 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
EP3802603A1 (en) 2018-06-04 2021-04-14 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients
US12312394B2 (en) 2018-06-28 2025-05-27 Alexion Pharmaceuticals, Inc. Methods of producing anti-C5 antibodies
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
EP3873602B1 (en) 2018-10-30 2023-12-06 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
AU2021337652B2 (en) 2020-09-04 2025-01-30 Alexion Pharmaceuticals, Inc. Methods for treating bone mineralization disorders
EP4232150A4 (en) * 2020-10-23 2025-01-01 Alexion Pharmaceuticals, Inc. METHOD FOR CONTROLLING TOTAL TIALIC ACID CONTENT DURING THE PRODUCTION OF ALKALINE PHOSPHATASE
BR112023016048A2 (pt) 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2224175B1 (https=) 1973-04-04 1978-04-14 Isf Spa
IT1017153B (it) 1974-07-15 1977-07-20 Isf Spa Apparecchio per inalazioni
US4234571A (en) 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
SE438261B (sv) 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
HU185535B (en) 1982-05-25 1985-02-28 Mta Koezponti Hivatala Process for preparing new gonadoliberin derivatives
GB8314308D0 (en) 1983-05-24 1983-06-29 Matburn Holdings Ltd Medical administration devices
US4840896A (en) 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
US4923805A (en) 1983-11-02 1990-05-08 Integrated Genetics, Inc. Fsh
US5156957A (en) 1983-11-02 1992-10-20 Genzyme Corporation Follicle stimulating hormone
US5639639A (en) 1983-11-02 1997-06-17 Genzyme Corporation Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof
EP0160699B1 (en) 1983-11-02 1992-08-12 Applied Research Systems Ars Holding N.V. Production of heterodimeric human fertlity hormones
US4589402A (en) 1984-07-26 1986-05-20 Serono Laboratories, Inc. Method of in vitro fertilization
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
JPH0779694B2 (ja) 1985-07-09 1995-08-30 カドラント バイオリソ−シズ リミテツド 蛋白質および同類品の保護
US5089423A (en) * 1987-05-06 1992-02-18 Cyberfluor Inc. Immunoassay methods and reagents and methods for producing the latter
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
JP3045539B2 (ja) 1989-02-21 2000-05-29 ワシントン ユニバーシティ 改変型生殖ホルモン
GB8909891D0 (en) 1989-04-28 1989-06-14 Riker Laboratories Inc Device
US5384132A (en) 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
US5270057A (en) 1990-03-20 1993-12-14 Akzo N.V. Stabilized gonadotropin containing preparations
US5580734A (en) 1990-07-13 1996-12-03 Transkaryotic Therapies, Inc. Method of producing a physical map contigous DNA sequences
IT1243344B (it) 1990-07-16 1994-06-10 Promo Pack Sa Inalatore plurimonodose per medicamenti in polvere
DE69230613T2 (de) 1991-07-02 2000-12-28 Inhale Inc Verfahren und vorrichtung zum abgeben von medikamenten in aerosolform
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
IT1250075B (it) 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
US5320094A (en) 1992-01-10 1994-06-14 The Johns Hopkins University Method of administering insulin
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
US5994314A (en) 1993-04-07 1999-11-30 Inhale Therapeutic Systems, Inc. Compositions and methods for nucleic acid delivery to the lung
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
IS1736B (is) 1993-10-01 1999-12-30 Astra Ab Aðferð og tæki sem stuðla að aukinni samloðun agna
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US6238890B1 (en) * 1994-02-18 2001-05-29 Washington University Single chain forms of the glycoprotein hormone quartet
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
SE9404468D0 (sv) 1994-12-22 1994-12-22 Astra Ab Powder formulations
ATE287703T1 (de) 1995-04-14 2005-02-15 Nektar Therapeutics Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5826633A (en) 1996-04-26 1998-10-27 Inhale Therapeutic Systems Powder filling systems, apparatus and methods
FR2754450B1 (fr) 1996-10-11 1998-12-31 3X Engineering Materiau support de microcapsules
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US5990288A (en) * 1997-10-21 1999-11-23 Vitro Diagnostics, Inc. Method for purifying FSH
AU1384199A (en) 1997-11-07 1999-05-31 Chiron Corporation Method for producing igf-1 sustained-release formulations
IL140984A0 (en) 1998-07-23 2002-02-10 Lilly Co Eli Fsh and fsh variant formulations, products and methods

Also Published As

Publication number Publication date
TWI277425B (en) 2007-04-01
CA2369262A1 (en) 2000-10-19
US7112341B1 (en) 2006-09-26
AU779869B2 (en) 2005-02-17
JP2002541213A (ja) 2002-12-03
EP1169053A1 (en) 2002-01-09
AU4082000A (en) 2000-11-14

Similar Documents

Publication Publication Date Title
HK1042234A1 (zh) 向肺部施加乾粉配方以治疗不育症
WO2001049274A3 (en) Methods for pulmonary delivery of interleukin-2
WO2002070438A3 (en) Compositions for delivering bisphosphonates
NO20021800D0 (no) Törre pulverblandinger med forbedret dispergerbarhet
WO2002080884A3 (en) Powder inhaler formulations
MY129263A (en) Vaccine composition
WO2003059276A3 (en) Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
WO2003002136A3 (en) Stable formulation of modified glp-1
WO2001005355A3 (en) Formulations for il-11
WO2005025535A3 (en) Methods for preparing pharmaceutical compositions
GB0100758D0 (en) Immunogenic complex method of preparation thereof and pharmaceutical compositions containing the same, useful for disease control
WO2004043363A8 (en) Protein-stabilized liposomal formulations of pharmaceutical agents
HUP0300593A3 (en) Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets
MY119181A (en) Aryl pyrimidine derivatives
WO2003035051A3 (en) The use of proton sequestering agents in drug formulations
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
WO2004017918A8 (en) Method of preparing dry powder inhalation compositions
CA2461517A1 (en) Nicotine formulations comprising cocoa and use thereof
WO2004093800A3 (en) Thyronamine derivatives and analogs and methods of use thereof
WO2001038303A3 (fr) Analogues de la vitamine d
WO2003079993A3 (en) hGH (HUMAN GROWTH HORMONE) FORMULATIONS FOR PULMONARY ADMINISTRATION
HUP0202233A3 (en) Derivatives and analogues of galanthamin, their use, pharmaceutical compositions containing them and process for the preparation of them
WO2000027340A3 (en) USE OF t-RNA AND FRAGMENTS FOR INHIBITING ANGIOGENESIS AND COMPOSITIONS THEREOF
SI1684719T1 (sl) Sestavki alfa antitripsina in postopki zdravljenja ob uporabi takih sestavkov
AU2003273473A1 (en) Novel substituted pyrazolo(1,5 less thanigreater thanaless than/igreater than)-1,3,5-triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same

Legal Events

Date Code Title Description
AS Change of ownership

Owner name: NEKTAR THERAPEUTICS

Free format text: FORMER OWNER(S): NEKTAR THERAPEUTICS, ELI LILLY AND COMPANY